Response Genetics, Inc.
| Nasdaq: RGDX
Response Genetics, Inc. is a life sciences company, which is engaged in the research and development of clinical diagnostic tests for cancer. It has developed technologies for the extraction of Ribonucleic acid (RNA) from formalin-fixed and paraffin-embedded tissues which enables to reliably recover RNA suitable for a variety of applications, such as gene expression research, development of diagnostics and microarray platforms. The company's platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. It also provides pharmacogenomic testing services of clinical trial specimens to pharmaceutical companies. The company was founded by David A. Smith and Kathleen Danenberg on September 23, 1999 and is headquartered in Los Angeles, CA.